Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2014 Jun 1;74(11):3104-13. doi: 10.1158/0008-5472.CAN-13-2235. Epub 2014 Mar 24.

Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations.

Author information

1
Authors' Affiliations: Departments of Medicine, Biochemistry and Molecular Pharmacology; The NYU Cancer Institute, New York University School of Medicine; and Departments of Pediatrics and Cell and Biology Development, Weill Cornell School of Medicine, New York, New York.
2
Authors' Affiliations: Departments of Medicine, Biochemistry and Molecular Pharmacology; The NYU Cancer Institute, New York University School of Medicine; and Departments of Pediatrics and Cell and Biology Development, Weill Cornell School of Medicine, New York, New YorkAuthors' Affiliations: Departments of Medicine, Biochemistry and Molecular Pharmacology; The NYU Cancer Institute, New York University School of Medicine; and Departments of Pediatrics and Cell and Biology Development, Weill Cornell School of Medicine, New York, New YorkAuthors' Affiliations: Departments of Medicine, Biochemistry and Molecular Pharmacology; The NYU Cancer Institute, New York University School of Medicine; and Departments of Pediatrics and Cell and Biology Development, Weill Cornell School of Medicine, New York, New York Lawrence.gardner@nyumc.org.

Abstract

Many of the gene mutations found in genetic disorders, including cancer, result in premature termination codons (PTC) and the rapid degradation of their mRNAs by nonsense-mediated RNA decay (NMD). We used virtual library screening, targeting a pocket in the SMG7 protein, a key component of the NMD mechanism, to identify compounds that disrupt the SMG7-UPF1 complex and inhibit NMD. Several of these compounds upregulated NMD-targeted mRNAs at nanomolar concentrations, with minimal toxicity in cell-based assays. As expected, pharmacologic NMD inhibition disrupted SMG7-UPF1 interactions. When used in cells with PTC-mutated p53, pharmacologic NMD inhibition combined with a PTC "read-through" drug led to restoration of full-length p53 protein, upregulation of p53 downstream transcripts, and cell death. These studies serve as proof-of-concept that pharmacologic NMD inhibitors can restore mRNA integrity in the presence of PTC and can be used as part of a strategy to restore full-length protein in a variety of genetic diseases.

PMID:
24662918
PMCID:
PMC4040335
DOI:
10.1158/0008-5472.CAN-13-2235
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center